Pharma & Biotech
You will receive alerts when there are new announcements on Akari Therapeutics
Only registered members can use this feature.
We are developing life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways.
© Proactive Investors 2019.
Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.